ATTACK (ASPIRIN TO TARGET ARTERIAL EVENTS IN CHRONIC KIDNEY DISEASE) is a pragmatic multicentre open-label randomised controlled trial to determine whether the addition of low-dose aspirin to usual care reduces the risk of major vascular events in people with chronic kidney disease (CKD) who do not have pre-existing cardiovascular disease (CVD). This is a very simple study, with a very low workload for participating practices.

This study, run by the same researchers as those managing the HEAT, FAST GOUT and ALL HEART primary care studies, is due to start in autumn 2018. Participating practices would receive service support costs to cover their time to help with this important study, and support would be provided.

Would your practice be interested in helping us with this national study?

The Trial Manager is Jen Dumbleton, and her contact details are as follows, email: jennifer.dumbleton@nottingham.ac.uk, phone: 0115 823 1053.